Xencor, Inc. (NASDAQ:XNCR) VP John R. Desjarlais Sells 68,684 Shares

Xencor, Inc. (NASDAQ:XNCR) VP John R. Desjarlais sold 68,684 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the sale, the vice president now directly owns 200,104 shares in the company, valued at approximately $4,698,441.92. This represents a 25.55 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Xencor Trading Down 0.5 %

XNCR opened at $23.50 on Friday. The stock has a market cap of $1.64 billion, a PE ratio of -7.34 and a beta of 0.66. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a twelve month low of $15.31 and a twelve month high of $26.84. The company has a fifty day moving average of $20.84 and a 200-day moving average of $20.37.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $10.70 million for the quarter, compared to the consensus estimate of $14.59 million. During the same period in the previous year, the business earned ($0.40) EPS. The firm’s revenue was down 81.9% compared to the same quarter last year. On average, sell-side analysts predict that Xencor, Inc. will post -3.79 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on XNCR. JPMorgan Chase & Co. lifted their price target on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. BMO Capital Markets restated an “outperform” rating and set a $34.00 price objective (up from $32.00) on shares of Xencor in a research note on Friday, November 8th. Royal Bank of Canada upped their price target on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Thursday, September 26th. Finally, Wedbush reiterated an “outperform” rating and set a $38.00 target price on shares of Xencor in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Xencor has a consensus rating of “Moderate Buy” and a consensus price target of $35.75.

Hedge Funds Weigh In On Xencor

Several institutional investors have recently made changes to their positions in XNCR. Quarry LP acquired a new position in shares of Xencor during the second quarter worth approximately $36,000. KBC Group NV increased its stake in Xencor by 63.5% in the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 1,213 shares during the last quarter. SG Americas Securities LLC bought a new position in Xencor in the 2nd quarter valued at $154,000. XTX Topco Ltd purchased a new stake in shares of Xencor during the 2nd quarter worth approximately $196,000. Finally, Rockefeller Capital Management L.P. bought a new stake in shares of Xencor in the third quarter valued at $205,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.